



UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 2801-18

BOTTAZZI et al.

C# M#

Serial No. 09/555,473

Group Art Unit: 1644

Examiner: Jamroz

Filed: February 26, 2002

Date: March 20, 2002

Title: PHARMACEUTICAL COMPOSITIONS CONTAINING THE LONG PENTRAXIN
PTX3

Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED

MAR 21 2002

TECH CENTER 1600/2900

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment 0 minus highest number
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 0 minus highest number
previously paid for 3 (at least 3) = 0 x \$ 84.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this
paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) \$ 0.00

☐ Please enter the previously unentered , filed

☐ Submission attached

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: Abstract; The Merck Index, Eleventh Edition, page 278, point 1835 0.00

Copy of previously submitted PT0-1449; copy of

Submission of Priority Documents dated 1/29/02

and copy of postcard receipt of 1/29/02

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
BJS:eaw

NIXON & VANDERHYE P.C.
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature:



#16 C

ES, 4/1/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BOTTAZZI et al.

Atty. Ref.: **2801-18**

Serial No. **09/555,473**

Group: **1644**

Filed: **February 26, 2002**

Examiner: **Jamroz**

For: **PHARMACEUTICAL COMPOSITIONS CONTAINING THE
LONG PENTRAXIN PTX3**

* * * * *

RECEIVED

March 20, 2002

MAR 21 2002

Assistant Commissioner for Patents
Washington, DC 20231

TECH CENTER 1600/2900

Sir:

AMENDMENT

Responsive to the Official Action dated December 20, 2001, entry and
consideration of the following amendments and remarks are requested.

IN THE ABSTRACT

Insert the attached Abstract after the claims pages.

IN THE SPECIFICATION

Amend the specification as follows.

Page 12, between lines 3 and 4, insert the following paragraph:

--Figure 1: Schematic representation of the cDNA fragment coding for the

human PTX3 protein subcloned in the Bam H1 site of pSG5 expression vector. The two
domains (N-terminal and C-terminal or pentraxin like) are indicated: the pentraxin like

C¹